Entero Enters Reverse Merger with Journey Therapeutics

Entero Therapeutics has announced a proposed reverse merger with Journey Therapeutics, a company specializing in next-generation nano-immunoconjugates (NIC) for cancer treatment. The merger, expected to be completed contingent on several conditions including equity financing and shareholder approval, will see Journey's shareholders taking 99% ownership of the combined entity, which will operate under the Journey name and apply for continued NASDAQ listing. The combined company aims to advance cancer therapies, targeting gynecological cancers, non-Hodgkin's lymphoma, among others, alongside Entero's drugs in development for gastrointestinal conditions. Led by Henry Ji, Journey's focus will be on pioneering targeted cancer therapies using NIC, an advanced platform surpassing traditional ADCs. The Mayo Clinic, involved in the development of Journey’s NIC platform, will benefit from any financial returns to support its mission. The merger positions both companies to tackle a substantial market, focusing their resources on potentially groundbreaking oncology and precision treatments.